^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
bacillus Calmette-Guerin (BCG)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Lacocca Family Foundation
Drug class:
TNF receptor modulator
Related drugs:
1d
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years (clinicaltrials.gov)
P2, N=100, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> May 2031 | Trial primary completion date: May 2028 --> May 2031
Enrollment closed • Trial completion date • Trial primary completion date
|
bacillus Calmette-Guerin (BCG)
1d
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes (clinicaltrials.gov)
P2, N=150, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Mar 2031 | Trial primary completion date: Mar 2027 --> Mar 2031
Enrollment closed • Trial completion date • Trial primary completion date
|
bacillus Calmette-Guerin (BCG)
over1year
Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia (clinicaltrials.gov)
P2, N=0, Withdrawn, Massachusetts General Hospital | Trial completion date: Jan 2023 --> Jan 2027 | Trial primary completion date: Jan 2023 --> Jan 2027
Trial completion date • Trial primary completion date
|
bacillus Calmette-Guerin (BCG)
2years
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes (clinicaltrials.gov)
P2, N=150, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jul 2027 --> Jul 2031 | Trial primary completion date: Jul 2025 --> Jul 2029
Trial completion date • Trial primary completion date
|
bacillus Calmette-Guerin (BCG)
Share via
